Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Effect a Reverse Stock Split

Friday, February 9, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. announced a reverse stock split as part of its strategy to enhance stock performance. The company is known for its innovative ARCUS platform, which focuses on developing in vivo gene editing therapies. This move is aimed at improving the company's market position and shareholder value.
Price reaction · baseline $11.994 (2024-02-08 close) · hit pre-market · 3 other DTIL headline(s) in the window, move may be shared
day 0 close
-4%
day 1
-6.2%
day 3
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing gene editing technologies.
  • The company is utilizing its proprietary ARCUS platform.
  • The reverse stock split may enhance stock performance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Feb. 9, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

What is the purpose of the reverse stock split?

The reverse stock split aims to enhance stock performance and improve market position.

What technology does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing therapies.

When was the reverse stock split announced?

The reverse stock split was announced on February 9, 2024.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform stock split
Last updated: Feb 9, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →